 |
|
Pathological Gambling Caused by Drugs Used to Treat Parkinson Disease
M. Leann Dodd, MD;
Kevin J. Klos, MD;
James H. Bower, MD;
Yonas E. Geda, MD;
Keith A. Josephs, MST, MD;
J. Eric Ahlskog, PhD, MD
Arch Neurol. 2005;62:1377-1381. Published online July 11, 2005 (doi:10.1001/archneur.62.9.noc50009).
Background Pathological gambling is a rare potential complication related to treatment of Parkinson disease (PD). However, the etiology of this behavior is poorly understood.
Objective To examine the relationship between medical therapy for PD and pathological gambling.
Methods In our routine movement disorders practice (2002-2004), we encountered 11 patients with idiopathic PD who had recently developed pathological gambling. We assessed the relationship to their medical therapy and compared them with cases identified by systematic review of the existing literature on pathological gambling and PD.
Results All 11 patients with PD and pathological gambling were taking therapeutic doses of a dopamine agonist; 3 of these patients were not treated with levodopa. In 7 patients, pathological gambling developed within 3 months of starting to take or escalating the dose of the agonist; in the other 4 with a longer latency, gambling resolved after the agonist use was discontinued. Pramipexole dihydrochloride was the agonist in 9 of 11 cases in our series and 10 of 17 in the literature (68% in total).
Conclusions Dopamine agonist therapy was associated with potentially reversible pathological gambling, and pramipexole was the medication predominantly implicated. This may relate to disproportionate stimulation of dopamine D3 receptors, which are primarily localized to the limbic system.
Author Affiliations: Departments of Psychiatry and Psychology (Drs Dodd and Geda) and Neurology (Drs Klos, Bower, Josephs, and Ahlskog), Mayo Clinic, Rochester, Minn.
RELATED LETTERS
Gambling and Parkinson Disease
Cathy Lu, Aamir Bharmal, and Oksana Suchowersky
Arch Neurol. 2006;63(2):298.
EXTRACT
| FULL TEXT
Impulse Control Disorders and Dopaminergic Drugs
John C. Morgan, Sanjay S. Iyer, and Kapil D. Sethi
Arch Neurol. 2006;63(2):298-299.
EXTRACT
| FULL TEXT
Impulse Control Disorders and Dopaminergic Drugs—Reply
M. Leann Dodd, Kevin J. Klos, James H. Bower, Yonas E. Geda, Keith A. Josephs, and J. Eric Ahlskog
Arch Neurol. 2006;63(2):299.
EXTRACT
| FULL TEXT
Association Between Pathologic Gambling and Parkinsonian Therapy as Detected in the Food and Drug Administration Adverse Event Database
Ana Szarfman, P. Murali Doraiswamy, Joseph M. Tonning, and Jonathan G. Levine
Arch Neurol. 2006;63(2):299-300.
EXTRACT
| FULL TEXT
Association Between Pathologic Gambling and Parkinsonian Therapy as Detected in the Food and Drug Administration Adverse Event Database—Reply
M. Leann Dodd
Arch Neurol. 2006;63(2):300.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Restless Legs Syndrome
Ryan and Slevin
Journal of Pharmacy Practice 2007;20:430-448.
ABSTRACT
Hold Your Horses: Impulsivity, Deep Brain Stimulation, and Medication in Parkinsonism
Frank et al.
Science 2007;318:1309-1312.
ABSTRACT
| FULL TEXT
Medication-Related Impulse Control and Repetitive Behaviors in Parkinson Disease
Voon and Fox
Arch Neurol 2007;64:1089-1096.
ABSTRACT
| FULL TEXT
Pathologic gambling in patients with restless legs syndrome treated with dopaminergic agonists
Tippmann-Peikert et al.
Neurology 2007;68:301-303.
ABSTRACT
| FULL TEXT
Recognition and management of neuropsychiatric complications in Parkinson's disease
Ferreri et al.
CMAJ 2006;175:1545-1552.
ABSTRACT
| FULL TEXT
Repetitive and impulsive behaviors in treated Parkinson disease.
Black and Friedman
Neurology 2006;67:1118-1119.
FULL TEXT
Clinical features associated with impulse control disorders in Parkinson disease.
Pontone et al.
Neurology 2006;67:1258-1261.
ABSTRACT
| FULL TEXT
Dopamine Receptor Agonists and Levodopa and Inducing Psychosis-Like Behavior in the MPTP Primate Model of Parkinson Disease.
Fox et al.
Arch Neurol 2006;63:1343-1344.
FULL TEXT
Association of Dopamine Agonist Use With Impulse Control Disorders in Parkinson Disease.
Weintraub et al.
Arch Neurol 2006;63:969-973.
ABSTRACT
| FULL TEXT
Prospective prevalence of pathologic gambling and medication association in Parkinson disease
Voon et al.
Neurology 2006;66:1750-1752.
ABSTRACT
| FULL TEXT
Patterns of initial pharmacotherapy for Parkinson's disease in the United States.
Huse et al.
J Geriatr Psychiatry Neurol 2006;19:91-97.
ABSTRACT
Pathological Gambling: Focusing on the Addiction, Not the Activity
Tamminga and Nestler
Am. J. Psychiatry 2006;163:180-181.
FULL TEXT
Gambling and Parkinson Disease
Lu et al.
Arch Neurol 2006;63:298-298.
FULL TEXT
Impulse Control Disorders and Dopaminergic Drugs--Reply
Dodd et al.
Arch Neurol 2006;63:299-299.
FULL TEXT
Association Between Pathologic Gambling and Parkinsonian Therapy as Detected in the Food and Drug Administration Adverse Event Database--Reply
Dodd
Arch Neurol 2006;63:300-300.
FULL TEXT
Impulse Control Disorders and Dopaminergic Drugs
Morgan et al.
Arch Neurol 2006;63:298-299.
FULL TEXT
Association Between Pathologic Gambling and Parkinsonian Therapy as Detected in the Food and Drug Administration Adverse Event Database
Szarfman et al.
Arch Neurol 2006;63:299-300.
FULL TEXT
Gambling on Dopamine Agonists
JWatch Psychiatry 2005;2005:6-6.
FULL TEXT
Betting on the D3 Receptor: Gambling and Dopaminergic Agonists
JWatch Neurology 2005;2005:3-3.
FULL TEXT
RAPID RESPONSES TO THIS ARTICLE
Gambling behavior with Primazpexole as treatment for Restless Legs Syndrome
Steven R Brenner
Arch Neurol Online, 9 Aug 2005.
TEXT
|
